Want to see NGNE full AI Analyst Report?
Top Page
Neurogene
(NASDAQ:NGNE)
Select Model
Select Model
Rating:58Neutral
Price Target:
$42.00
▲(2.84% Upside)
Action:Reiterated
Date:08/18/26
The score is held back primarily by weak financial performance (no meaningful revenue and expanding losses with rising cash burn), despite a comparatively solid low-debt balance sheet. Offsetting this, technicals are constructive with price above major moving averages and positive MACD, and corporate events are supportive due to an extended cash runway and positive NGN-401 clinical/program milestones. Valuation is only moderately supportive because the negative P/E reflects ongoing losses and there is no dividend yield data.
Positive Factors
Extended Cash Runway
Funding through early 2029 gives Neurogene time to advance clinical programs without immediate refinancing pressure. This supports sustained R&D execution, though future capital needs remain dependent on development progress.
Negative Factors
Pre-Revenue Business Model
Neurogene has no established commercial revenue base to offset substantial development spending. The company therefore remains dependent on successful clinical and regulatory outcomes before it can build recurring product revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended Cash Runway
Funding through early 2029 gives Neurogene time to advance clinical programs without immediate refinancing pressure. This supports sustained R&D execution, though future capital needs remain dependent on development progress.
Read all positive factors
Neurogene (NGNE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$768.64M
Dividend YieldN/A
Average Volume (3M)270.69K
Price to Earnings (P/E)―
Beta (1Y)3.12
Revenue GrowthN/A
EPS Growth-18.84%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.51
Shares Outstanding20,011,381
10 Day Avg. Volume213,349
30 Day Avg. Volume270,693
Financial Highlights & Ratios
PEG Ratio5.20
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$81.83Price Target Upside100.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.51
Revenue Forecast (FY)N/A
Neurogene Business Overview & Revenue Model
Company Description
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-4...
How the Company Makes Money
As a clinical-stage biotechnology company, Neurogene does not have publicly available, consistent evidence of recurring product sales; therefore, its revenue model is primarily tied to biotechnology financing and any collaboration-related income. ...
Neurogene Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
68
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 925.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -18.88M | -3.19M | -2.32M | -3.26M | -3.20M | -42.26M |
| EBITDA | -106.31M | -87.25M | -71.89M | -33.01M | -51.99M | -49.57M |
| Net Income | -111.11M | -90.35M | -75.14M | -36.32M | -55.19M | -50.52M |
Balance Sheet | ||||||
| Total Assets | 244.36M | 288.60M | 335.73M | 222.57M | 109.27M | 101.49M |
| Cash, Cash Equivalents and Short-Term Investments | 225.39M | 269.01M | 312.40M | 197.16M | 82.02M | 70.54M |
| Total Debt | 8.35M | 9.89M | 12.43M | 16.25M | 4.69M | 6.43M |
| Total Liabilities | 27.23M | 23.72M | 25.36M | 36.55M | 10.64M | 193.36M |
| Stockholders Equity | 217.13M | 264.89M | 310.38M | 186.02M | 98.63M | -91.88M |
Cash Flow | ||||||
| Free Cash Flow | -87.11M | -78.36M | -71.41M | -51.74M | -55.05M | -64.77M |
| Operating Cash Flow | -86.24M | -77.17M | -70.60M | -51.42M | -52.82M | -46.40M |
| Investing Cash Flow | 104.66M | 14.00M | -125.26M | 25.64M | -2.23M | -18.37M |
| Financing Cash Flow | 36.61M | 30.43M | 184.07M | 92.48M | 66.53M | 51.06M |
Neurogene Technical Analysis
Positive
40.84
Price Trends
35.62
Positive
31.43
Positive
25.82
Positive
Market Momentum
1.11
Negative
53.67
Neutral
58.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NGNE, the sentiment is Positive. The current price of 40.84 is above the 20-day moving average (MA) of 36.68, above the 50-day MA of 35.62, and above the 200-day MA of 25.82, indicating a bullish trend. The MACD of 1.11 indicates Negative momentum. The RSI at 53.67 is Neutral, neither overbought nor oversold. The STOCH value of 58.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NGNE.
Neurogene Risk Analysis
Neurogene disclosed 88 risk factors in its most recent earnings report. Neurogene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Neurogene Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $441.93M | -2.62 | -64.25% | ― | ― | -29.71% | |
59 Neutral | $814.64M | -3.53 | -106.90% | ― | ― | ― | |
58 Neutral | $768.64M | -6.87 | -45.11% | ― | ― | -18.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.40B | -0.07 | -91.63% | ― | ― | 69.48% | |
46 Neutral | $156.11M | -1.31 | -108.05% | ― | ― | 45.08% | |
45 Neutral | $78.32M | -1.41 | -1266.43% | ― | ― | 49.43% |
* Healthcare Sector Average
NGNE
Neurogene
36.58
18.10
97.94%
SLN
Silence Therapeutics
13.42
8.61
179.00%
AVIR
Atea Pharmaceuticals
5.36
2.00
59.52%
ELTX
Elicio Therapeutics
2.84
-7.69
-73.03%
VOR
Vor Biopharma
22.65
-16.75
-42.51%
TNYA
Tenaya Therapeutics
0.69
-0.44
-38.94%
Neurogene Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Neurogene bolsters cash runway with equity offering
Positive
Jul 2, 2026
On June 30, 2026, Neurogene Inc. entered an underwriting agreement with Leerink Partners, Stifel Nicolaus, and Guggenheim Securities for a public offering of 3,500,000 shares at $30.00 each and pre-funded warrants for 666,666 shares at a near-equi...
Business Operations and StrategyProduct-Related Announcements
Neurogene reports promising long-term NGN-401 Rett data
Positive
Jun 29, 2026
On June 29, 2026, Neurogene reported updated long-term data from its Phase 1/2 trial of NGN-401 gene therapy in females with Rett syndrome, showing 47 developmental milestones gained across 10 participants, with a median two-month time to first im...
Business Operations and StrategyProduct-Related Announcements
Neurogene Completes Dosing in Embolden Rett Trial
Positive
Jun 8, 2026
On June 8, 2026, Neurogene announced that it had successfully completed dosing in its Embolden registrational trial of NGN-401 for Rett syndrome, exceeding its original enrollment target by treating 25 participants due to strong patient demand. Th...
Executive/Board ChangesShareholder Meetings
Neurogene Stockholders Vote on Directors and Executive Pay
Neutral
Jun 4, 2026
On June 3, 2026, Neurogene Inc. held its 2026 Annual Meeting of Stockholders, where a quorum of approximately 72.92% of eligible voting power was present in person or by proxy. Stockholders elected Class III directors Robert Baffi and Rohan Paleka...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.